Treating COVID-19 by traditional Chinese medicine: a charming strategy?

Journal Title: Traditional Medicine Research - Year 2020, Vol 5, Issue 4

Abstract

On April 14, 2020, the State Council of China announced that “three proprietary Chinese medicines and three decoctions” of effective traditional Chinese medicine (TCM) in the treatment of the novel coronavirus pneumonia have passed clinical practice screenings [1]. Some scholars believe that early TCM intervention of mild and moderate cases and recovery period may reduce the ratio of mild cases progressing into severe and critical cases. Some data have also suggested that the combination of TCM and Western medicine may reduce the mortality rate in severe and critical cases [2, 3]. The “three proprietary Chinese medicines” are Chinese patent drug Jinhua Qinggan granules (approval number of State Food and Drug Administration of China (SFDA) Z20160001), Lianhua Qingwen granules (SFDA approval number Z20100040), and Xuebijing injection (SFDA approval number Z20040033) [4]. In this regard, the National Medical Products Administration of China recently approved the inclusion of the treatment of the novel coronavirus pneumonia as a new indication of the “three proprietary Chinese medicines”, which have become the world’s first batch of drugs suitable for COVID-19 (Table 1) [5]. The “three decoctions” are empirical formula of Chinese medicine Qingfei Paidu decoction, Huashi Baidu decoction, and Xuanfei Baidu decoction (Table 2). Among them, Qingfei Paidu granules and Huashi Baidu granule have been recently approved for clinical trials [5]. Jinhua Qinggan granule is a proprietary Chinese medicine developed during the 2009 H1N1 influenza pandemic. Both Lianhua Qingwen capsule and Xuebijing injection were identified as proprietary Chinese medicines developed and listed during the SARS in 2003 [3–5]. At present, 22 TCM treatment programs have been registered for clinical trials. However, because Lianhua Qingwen capsule contains Houttuynia cordata, Qingfei Paidu decoction contains Belamcandae Rhizoma, and both of them contain aristolochic acid, which can cause kidney injury and liver cancer [6–7]. Xuanfei Baidu decoction and Qingfei Paidu decoction contain Ephedrae Herba, which has cardiovascular toxicity and stimulative effect on central nervous system [8]. Qingfei Paidu decoction contains Alismatis Rhizoma, which may cause kidney injury [9]. Perhaps it is the above toxicity of herb that prohibits the import or clinical application of these six decoctions in Sweden, Singapore, the United States, Canada and other countries [10].

Authors and Affiliations

Yu-Liang Zhang,Wan-Ying Zhang,Xin-Zhe Zhao,Jia-Ming Xiong,Guo-Wei Zhang

Keywords

Related Articles

The effect of hot intermittent cupping on pain, stiffness and disability of patients with knee osteoarthritis

Objective: The aim of this study was to investigate the effect of hot intermittent cupping on pain, stiffness and inability of patients with knee osteoarthritis (KO). Methods: The present study was a clinical trial, whic...

Camel milk could be helpful in the treatment of asthma

Asthma is a chronic inflammatory disease with excessive irritability and airway narrowing and inflammation plays an important role in it. There are 300 million asthmatic people in the world currently. Main treatments for...

Effect of Jianpi Jiedu Recipe on angiogenesis and the PTEN/PI3K/AKT signaling pathway in the course of Helicobacter pylori-induced gastric cancer in C57BL/6 mice

Objective: To reveal the effect of Jianpi Jiedu recipe (JPJDR) on angiogenesis and the PTEN (Phosphatase and tensin homolog deleted on chromosome ten)/PI3K/AKT signaling pathway in the course of H. pylori infection-induc...

Annual advances of integrative pharmacology in 2020

Major studies on the pharmacology of traditional herbs as well as active compounds have been introduced in this review over the previous 12 months. This annual integrative pharmacology review includes the reports publish...

Gastrointestinal effects of Artemisia absinthium Linn. based on traditional Persian medicine and new studies

One of the most extensively used herbs in traditional Persian medicine (TPM) used in the treatment of gastrointestinal (GI) disorders, is the plant Artemisia absinthium Linn. (AAL). It also has a wide range of activities...

Download PDF file
  • EP ID EP683783
  • DOI 10.12032/TMR20200515179
  • Views 203
  • Downloads 0

How To Cite

Yu-Liang Zhang, Wan-Ying Zhang, Xin-Zhe Zhao, Jia-Ming Xiong, Guo-Wei Zhang (2020). Treating COVID-19 by traditional Chinese medicine: a charming strategy?. Traditional Medicine Research, 5(4), -. https://europub.co.uk./articles/-A-683783